Carregando empresa
Just reported
Q3 2026 results
From Sutro Biopharma's results release of 12 de novembro de 2026. These are the company's first figures; its 10-Q or 10-K replaces them when filed.
Revenue
Actual
US$ 9,1M
-6,1% y/y
-7,5% q/qGuided
—
No guide given
Operating income, GAAP
Actual
-US$ 22M
Guided
—
No guide given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
Keep exploring
The themes Sutro Biopharma is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Highest-graded in Biotechnology
Graded A or B and worth $2B or more: A first, then the largest.
ONCBeone Medicines Ltd.US$ 48BA+
EXELExelixis, Inc.US$ 17,3BA+
JAZZJazz Pharmaceuticals plcUS$ 15,9BA
HALOHalozyme Therapeutics, Inc.US$ 11,6BA+
TECHBIO-Techne CorpUS$ 11,4BA+
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation21 de out. de 2026CBGraded C, now B
MCKMckesson Corporation4 de nov. de 2026BAGraded B, now A
CVSCVS Health Corp4 de nov. de 2026BAGraded B, now A
EWEdwards Lifesciences Corporation4 de nov. de 2026BAGraded B, now A
BIIBBiogen Inc.28 de out. de 2026BAGraded B, now A
Demonstrações financeiras completas →
Construído a partir dos próprios documentos de Sutro Biopharma, Inc. entregues à Comissão de Valores Mobiliários dos EUA (SEC). Os números são os divulgados, com o histórico por ação recalculado para a base de ações de hoje. Isto descreve um negócio — não é recomendação de investimento nem sugestão de compra ou venda.
